Trial Profile

A Phase 1, Randomized, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, And Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 23 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Treprostinil palmitil (Primary)
Indications Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension; Pulmonary hypertension
Focus Adverse reactions; First in man
Sponsors Insmed

07 Sep 2022 Results assessing the safety, tolerability, and pharmacokinetics of TP and treprostinil following single and multiple QD administrations of TPIP in healthy volunteers, published in the Advances in Therapy.
05 Aug 2021 According to an Insmed media release, the company plans to present full data from this study t the European Society of Cardiology Congress on August 30, 2021.
19 Feb 2021 Status changed from recruiting to completed, according to an Insmed media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com